Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19044281 | 0.84 | CYP1A2 (0.49) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL25594845 | 0.82 | CYP1A2 (0.44) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL1008113 | 0.77 | CYP1A2 (0.48) | CYP1A2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6381168 | 0.73 | CYP1A2 (0.44) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2POLB | |
| SCHEMBL6381453 | 0.71 | ALDH1A1 (0.42) | CYP1A2ALDH1A1CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL30926615 | 0.71 | CYP1A2 (0.65) | CYP1A2 | |
| SCHEMBL13423899 | 0.70 | CYP1A2 (0.41) | CYP1A2ALDH1A1 | |
| SCHEMBL13424047 | 0.68 | CYP1A2 (0.48) | CYP1A2ALDH1A1KDM4E | |
| SCHEMBL31353905 | 0.68 | PDCD1 (0.48) | — | |
| SCHEMBL16285299 | 0.68 | CYP1A2 (0.45) | CYP1A2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | CYP1A2 957/4885ALDH1A1 651/4885CYP2C19 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.